Journal article icon

Journal article

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

Abstract:

PURPOSE: We conducted a retrospective analysis to evaluate the safety and efficacy of Campath-1H, an anti-CD52 humanized monoclonal antibody, in previously treated T-prolymphocytic leukemia (T-PLL) patients in a compassionate-use program. PATIENTS AND METHODS: Seventy-six patients with T-PLL (including four chemotherapy-naive patients) received 3, 10, and 30 mg of Campath-1H on sequential days, followed by 30 mg three times weekly, as 2-hour intravenous infusions, for 4 to 12 weeks. RESULTS:...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1200/jco.20.1.205

Authors


Keating, MJ More by this author
Coutré, S More by this author
Birhiray, R More by this author
Kovacsovics, T More by this author
Expand authors...
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume:
20
Issue:
1
Pages:
205-213
Publication date:
2002-01-05
DOI:
EISSN:
1527-7755
ISSN:
0732-183X
URN:
uuid:e3f646b4-08e3-4741-bcd3-ed070a1188bc
Source identifiers:
237017
Local pid:
pubs:237017

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP